Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Position Lifted by OxFORD Asset Management LLP

OxFORD Asset Management LLP raised its stake in shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) by 42.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,040,297 shares of the biopharmaceutical company’s stock after buying an additional 608,402 shares during the quarter. OxFORD Asset Management LLP owned about 0.91% of Synergy Pharmaceuticals worth $5,784,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Alliancebernstein L.P. lifted its holdings in shares of Synergy Pharmaceuticals by 25.9% during the 2nd quarter. Alliancebernstein L.P. now owns 339,330 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 69,800 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Synergy Pharmaceuticals by 18.2% during the 2nd quarter. Sei Investments Co. now owns 367,779 shares of the biopharmaceutical company’s stock valued at $1,637,000 after purchasing an additional 56,595 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Synergy Pharmaceuticals by 14.4% during the 2nd quarter. Swiss National Bank now owns 371,650 shares of the biopharmaceutical company’s stock valued at $1,654,000 after purchasing an additional 46,800 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Synergy Pharmaceuticals by 60.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,988,200 shares of the biopharmaceutical company’s stock valued at $8,848,000 after purchasing an additional 752,475 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new position in shares of Synergy Pharmaceuticals during the 2nd quarter valued at about $730,000. Institutional investors own 60.52% of the company’s stock.

SGYP has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price objective on shares of Synergy Pharmaceuticals in a report on Friday, September 8th. BTIG Research reiterated a “buy” rating and set a $11.00 price objective on shares of Synergy Pharmaceuticals in a report on Friday, September 8th. HC Wainwright set a $7.00 price objective on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 4th. Citigroup reiterated a “sell” rating and set a $2.50 price objective (down previously from $3.20) on shares of Synergy Pharmaceuticals in a report on Wednesday, September 13th. Finally, ValuEngine cut Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Three analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.84.

In other Synergy Pharmaceuticals news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $2.82, for a total transaction of $24,675,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.80% of the stock is owned by insiders.

Shares of Synergy Pharmaceuticals, Inc. (SGYP) opened at $2.01 on Thursday. The company has a quick ratio of 3.88, a current ratio of 4.26 and a debt-to-equity ratio of -68.13. Synergy Pharmaceuticals, Inc. has a 12 month low of $1.68 and a 12 month high of $7.15.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. The firm had revenue of $5.01 million during the quarter, compared to the consensus estimate of $4.53 million. During the same quarter in the previous year, the firm posted ($0.22) EPS. analysts predict that Synergy Pharmaceuticals, Inc. will post -1.04 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://weekherald.com/2017/12/14/synergy-pharmaceuticals-inc-sgyp-shares-bought-by-oxford-asset-management-llp.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply